Benitec in the clinic
Friday, 06 June, 2008
Early signs from a Benitec (ASX: BLT) pilot study using RNA interference (RNAi) for AIDS-related lymphoma have proved promising, a panel heard.
Dr John Zaia, chair of the virology division at Beckman Research Institute in California, told attendees at the 11th annual meeting of the American Society of Gene Therapy that the gene treatment was proving to be effective so far.
Patients with AIDS-related lymphoma are being treated using vector-expressed RNAi, aimed at rendering the cells resistant to HIV infection.
Zaia presented data from 60 days of the study on the first two patients. Safe engraftment was seen at 10 days and gene markers are detectable.
According to Benitec, the initial results of this study indicate that if HIV+ patients undertake gene grafting shortly after infection, it could delay their need for antiviral chemotherapy, an invasive and exhausting treatment.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
